Peter Raymond Flatt
11Patents
5h-index
10Co-inventors
63Inventor score
Filing activity: Dec 15, 1993 → Aug 27, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7326688B2 | Analogs of gastric inhibitory polypeptide and their use of treatment for diabetes | Human Necessities | 39 | Expired |
| US7875587B2 | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity | Emerging Cross-Sectional Technologies | 12 | Active |
| US6921748B1 | Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes | Human Necessities | 12 | Expired |
| US5430188A | Process for the preparation of 2-alkyl-6-methyl-N-(1'-methoxy-2'-propyl)-aniline and a process for the preparation of their chloracetanilides | Chemistry; Metallurgy | 9 | Expired |
| US7666838B2 | Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes | Human Necessities | 7 | Active |
| US7402663B2 | Modified peptide | Human Necessities | 3 | Expired |
| US11541019B2 | Compositions for use in the treatment of diabetes | Human Necessities | 0 | Active |
| US10202427B2 | Esculentin-2CHa peptide and analogues thereof | Human Necessities | 0 | Active |
| US9060991B2 | Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission | Human Necessities | 0 | Active |
| US10118954B2 | Apelin analogues | Human Necessities | 0 | Active |
| US9062125B2 | Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.